Adding a PCSK9 Inhibitor or Ezetimibe to a Statin.

[Argirios Argiriou]

Bruce Soloway, MD, reviewing Khan SU et al. BMJ 2022 May 4 Hao Q et al. BMJ 2022 May 4

Adding a PCSK9 Inhibitor or Ezetimibe to a Statin Lowers Cardiovascular Risk in High-Risk Patients

But in a meta-analysis, adding a second agent had no benefit in those at moderate and low risk.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος